[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20221338A1 - Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina - Google Patents

Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina

Info

Publication number
PE20221338A1
PE20221338A1 PE2022000823A PE2022000823A PE20221338A1 PE 20221338 A1 PE20221338 A1 PE 20221338A1 PE 2022000823 A PE2022000823 A PE 2022000823A PE 2022000823 A PE2022000823 A PE 2022000823A PE 20221338 A1 PE20221338 A1 PE 20221338A1
Authority
PE
Peru
Prior art keywords
lurbinectedin
treatment
lung cancer
small cell
cell lung
Prior art date
Application number
PE2022000823A
Other languages
English (en)
Inventor
Pilar Calvo
Carmen Kahatt
Jose Maria Fernandez
Maria Tobio
Salvador Fudio
Arturo Soto
Pilar Lardelli
Cristian Fernandez
Alba Maria Del Mar Zarzuelo
Noain Maria De La Concepcion Polanco
Lopez Sonia Manzanaro
Honorio Velasco
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2020/063734 external-priority patent/WO2021228414A1/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PE20221338A1 publication Critical patent/PE20221338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere al uso de lurbinectedina para el tratamiento del cancer de pulmon de celulas pequenas (CPCP) a traves de un metodo de tratamiento que comprende: (1) administrar una dosis de corticosteroide y un antagonista de la serotonina para reducir las nauseas; y (2) administrar lurbinectedina a una dosis de 2 a 3.2 mg/m2 al paciente mediante infusion intravenosa; el corticosteroide es dexametasona administrada por via intravenosa a una dosis de 8 mg.
PE2022000823A 2019-11-21 2020-05-29 Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina PE20221338A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19383025 2019-11-21
EP20382409 2020-05-14
PCT/EP2020/063734 WO2021228414A1 (en) 2020-05-14 2020-05-15 Methods of treating small cell lung cancer with lurbinectedin formulations
PCT/EP2020/065093 WO2021098992A1 (en) 2019-11-21 2020-05-29 Methods of treating small cell lung cancer with lurbinectedin formulations

Publications (1)

Publication Number Publication Date
PE20221338A1 true PE20221338A1 (es) 2022-09-13

Family

ID=70918456

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000823A PE20221338A1 (es) 2019-11-21 2020-05-29 Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina

Country Status (18)

Country Link
US (6) US20230027502A1 (es)
EP (1) EP4061372A1 (es)
JP (1) JP2023503318A (es)
KR (1) KR20220119618A (es)
CN (1) CN115151259B (es)
AU (1) AU2020388196A1 (es)
BR (1) BR112022009283A2 (es)
CA (1) CA3158733A1 (es)
CL (1) CL2022001342A1 (es)
CO (1) CO2022008437A2 (es)
CR (1) CR20220289A (es)
EC (1) ECSP22049008A (es)
IL (1) IL293128A (es)
JO (1) JOP20220118A1 (es)
MX (1) MX2022006208A (es)
PE (1) PE20221338A1 (es)
SA (1) SA522432668B1 (es)
WO (1) WO2021098992A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022381992A1 (en) * 2021-11-08 2024-05-16 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
WO2024121864A1 (en) * 2022-12-09 2024-06-13 Rk Pharma Inc Ready-to-use injectable formulations of lurbinectedin
WO2024131887A1 (zh) * 2022-12-22 2024-06-27 博瑞生物医药（苏州）股份有限公司 一种含卢比替定的药物组合物及其制备方法和应用
WO2024133947A1 (en) * 2022-12-23 2024-06-27 Pharma Mar, S.A. Lurbinectedin and cyp3a4 inhibitor combination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
WO2005077341A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
CN103038240A (zh) * 2010-05-25 2013-04-10 法马马有限公司 制备海鞘素化合物的合成方法
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Also Published As

Publication number Publication date
CN115151259A (zh) 2022-10-04
US20240041872A1 (en) 2024-02-08
US20230390285A1 (en) 2023-12-07
KR20220119618A (ko) 2022-08-30
WO2021098992A1 (en) 2021-05-27
US20230027502A1 (en) 2023-01-26
US20240041874A1 (en) 2024-02-08
BR112022009283A2 (pt) 2022-08-02
JOP20220118A1 (ar) 2023-01-30
EP4061372A1 (en) 2022-09-28
AU2020388196A1 (en) 2022-06-30
CA3158733A1 (en) 2021-05-27
SA522432668B1 (ar) 2024-08-05
IL293128A (en) 2022-07-01
ECSP22049008A (es) 2022-08-31
CN115151259B (zh) 2024-09-27
MX2022006208A (es) 2022-07-05
US20230390286A1 (en) 2023-12-07
CO2022008437A2 (es) 2022-07-29
CR20220289A (es) 2022-10-27
US20240041873A1 (en) 2024-02-08
CL2022001342A1 (es) 2023-03-17
JP2023503318A (ja) 2023-01-27

Similar Documents

Publication Publication Date Title
PE20221338A1 (es) Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
RU2017134443A (ru) Способ лечения с применением традипитанта
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
JP2018526460A5 (es)
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
CR20190203A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
JP2019535830A5 (es)
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR105087A1 (es) Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
RU2013126798A (ru) Комбинированная терапия дексаметазоном
AR108792A1 (es) Composiciones que comprenden timolol
AR114012A1 (es) Método para proporcionar terapia de celiprolol a un paciente
MX2024006799A (es) Metodos para el tratamiento de cáncer con prame positivo.